This will be a randomized, open-label study to determine if camostat+ bicalutamide decreases
the proportion of people with COVID-19 who require hospitalization, compared to historical
controls. Patients with symptomatic COVID-19, diagnosed as outpatients, will be randomized
1:1, stratified by gender, to treatment with standard of care alone (Arm 1) or with camostat
and bicalutamide (Arm 2).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins